Combination vs monotherapy in pancreatic ductal adenocarcinoma

Speaker: John P. Neoptolemos

Given the toxicity profile and efficacy results, the combination regimen of gemcitabine and capecitabine is a new standard in adjuvant care of resected pancreatic ductal adenocarcinoma (PDAC) says J. Neoptolemos. He further digs into results, presented at ASCO 2016 Annual Meeting, of combination regimen with hypoxia-activated prodrug evofosfamide and gemcitabine in previously untreated metastatic or locally advanced unresectable PDAC.

Discussion Points

  • Rationale for the study
  • Key study findings
  • Practice perspective

Abstract  LBA4006: ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.                                      

Abstract 4007: MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).